Alginate-antacid combinations: raft formation and gastric retention studies

Background: Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories. Those containing alginate as the principle active agent and those containing alginate in combination with a significant amount of antacid. Method: The effectiveness of...

Full description

Saved in:
Bibliographic Details
Published in:Drug development and industrial pharmacy 2010-05, Vol.36 (5), p.614-623
Main Authors: Hampson, Frank C., Jolliffe, Ian G., Bakhtyari, Arash, Taylor, Glyn, Sykes, John, Johnstone, Lesley M., Dettmar, Peter W.
Format: Article
Language:English
Subjects:
Adult
Alginate
Alginates - administration & dosage
Alginates - pharmacokinetics
antacid
Antacids - administration & dosage
Antacids - pharmacokinetics
Chemistry, Pharmaceutical - instrumentation
Chemistry, Pharmaceutical - methods
Cross-Over Studies
Drug Combinations
Food-Drug Interactions - physiology
formulation
gastric retention
gastroesophageal reflux
Gastroesophageal Reflux - diagnostic imaging
Gastroesophageal Reflux - drug therapy
Glucuronic Acid - administration & dosage
Glucuronic Acid - pharmacokinetics
Hexuronic Acids - administration & dosage
Hexuronic Acids - pharmacokinetics
Humans
Male
Radionuclide Imaging
raft
Stomach - diagnostic imaging
Stomach - drug effects
Stomach - metabolism
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories. Those containing alginate as the principle active agent and those containing alginate in combination with a significant amount of antacid. Method: The effectiveness of the raft formed by a new alginate antacid suspension (Gaviscon Double Action Liquid, GDAL), in which calcium carbonate was the main antacid ingredient, was compared with those of existing alginate antacid suspensions. Result: GDAL had similar raft strength and improved raft resilience than Gaviscon Liquid (GL), and both were significantly greater than five other products tested. Gastric retention of GDAL was similar to that of GL. Conclusion: the in vitro and in vivo performance is maintained in the new GDAL formulation even with higher antacid levels and the product is as good as, or better than, previous formulations.
ISSN:0363-9045
1520-5762
DOI:10.3109/03639040903388290